Insmed/$INSM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Insmed
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Ticker
$INSM
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
1,271
Website
Insmed Metrics
BasicAdvanced
$21B
-
-$5.89
0.79
-
Price and volume
Market cap
$21B
Beta
0.79
52-week high
$108.89
52-week low
$60.40
Average daily volume
3.9M
Financial strength
Current ratio
5.863
Quick ratio
5.213
Long term debt to equity
1,310.342
Total debt to equity
1,316.957
Interest coverage (TTM)
-9.76%
Profitability
EBITDA (TTM)
-849.835
Gross margin (TTM)
76.49%
Net profit margin (TTM)
-265.93%
Operating margin (TTM)
-225.44%
Effective tax rate (TTM)
-0.40%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
-36.25%
Return on equity (TTM)
554.23%
Valuation
Price to revenue (TTM)
49.105
Price to book
199.38
Price to tangible book (TTM)
-209.57
Price to free cash flow (TTM)
-23.707
Free cash flow yield (TTM)
-4.22%
Free cash flow per share (TTM)
-4.585
Growth
Revenue change (TTM)
20.77%
Earnings per share change (TTM)
12.93%
3-year revenue growth (CAGR)
23.69%
3-year earnings per share growth (CAGR)
15.94%
10-year earnings per share growth (CAGR)
11.27%
What the Analysts think about Insmed
Analyst ratings (Buy, Hold, Sell) for Insmed stock.
Bulls say / Bears say
Insmed's experimental drug for pulmonary arterial hypertension (PAH) demonstrated significant efficacy in a Phase 2b study, leading to a 29% surge in stock price and plans for Phase 3 trials in late 2025. (biopharmadive.com)
The company's lead product, ARIKAYCE, achieved a 19% annual revenue growth in 2024, totaling $363.7 million, exceeding guidance and indicating strong market demand. (pr.comtex.com)
Brensocatib, targeting non-cystic fibrosis bronchiectasis, showed positive Phase 3 results, with an FDA New Drug Application accepted and a potential U.S. launch in mid-2025. (pr.comtex.com)
Insmed reported a net loss of $913.8 million for 2024, raising concerns about its financial sustainability despite revenue growth. (pr.comtex.com)
The company carries a high debt load of $1.1 billion, which could limit financial flexibility and increase risk for investors. (panabee.com)
Insider selling, including CEO William Lewis selling 18,750 shares in March 2025, may signal potential concerns about the company's future prospects. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
Insmed Financial Performance
Revenues and expenses
Insmed Earnings Performance
Company profitability
Insmed News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Insmed stock?
Insmed (INSM) has a market cap of $21B as of August 04, 2025.
What is the P/E ratio for Insmed stock?
The price to earnings (P/E) ratio for Insmed (INSM) stock is 0 as of August 04, 2025.
Does Insmed stock pay dividends?
No, Insmed (INSM) stock does not pay dividends to its shareholders as of August 04, 2025.
When is the next Insmed dividend payment date?
Insmed (INSM) stock does not pay dividends to its shareholders.
What is the beta indicator for Insmed?
Insmed (INSM) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.